TR
EN
Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
Abstract
Aim: In daily practice, everolimus plus exemestane therapy has begun to be used in the later-lines as it has been demonstrated that treatments such as cyclin-dependent kinase (CDK) 4/6 inhibitors and fulvestrant, alone or in combination, are more effective in hormone receptor (HR)-positive metastatic breast cancer (MBC). The aim of this study is to evaluate the efficacy and toxicity of everolimus plus exemestane in the third line and later-lines on HR-positive Human Epidermal Growth Factor Receptor 2 (HER2)-negative MBC treatment with real-life data.
Methods: Patients who received everolimus plus exemestane with the diagnosis of HR-positive and HER2-negative MBC between November 2013 and March 2020 were included in this retrospective cohort study. Clinicopathological characteristics of patients and treatment related toxicities were evaluated retrospectively.
Results: The median age of the 33 patients included in the study was 59 (30-77) years. Twenty-three (69.7%) of the patients had visceral metastasis, while 10 (30.3%) had only bone metastasis. Everolimus plus exemestane was used in the third line in 22 (66.6%) patients and later-lines in 11 (33.3%) patients. The median follow-up time was 15.5 months (0.3-35.5). Median progression-free survival (PFS) and overall survival (OS) were 7.0 (5.1-9.0, 95% CI) months and 21.3 (13.4-29.2, 95% CI) months, respectively. Median PFS of patients with only bone metastasis and visceral metastasis were similar (7.2 vs 6.4 months, P=0.96).
Conclusion: Everolimus plus exemestane is an effective and tolerable treatment choice in the later-lines in the treatment of HR-positive HER2-negative MBC.
Methods: Patients who received everolimus plus exemestane with the diagnosis of HR-positive and HER2-negative MBC between November 2013 and March 2020 were included in this retrospective cohort study. Clinicopathological characteristics of patients and treatment related toxicities were evaluated retrospectively.
Results: The median age of the 33 patients included in the study was 59 (30-77) years. Twenty-three (69.7%) of the patients had visceral metastasis, while 10 (30.3%) had only bone metastasis. Everolimus plus exemestane was used in the third line in 22 (66.6%) patients and later-lines in 11 (33.3%) patients. The median follow-up time was 15.5 months (0.3-35.5). Median progression-free survival (PFS) and overall survival (OS) were 7.0 (5.1-9.0, 95% CI) months and 21.3 (13.4-29.2, 95% CI) months, respectively. Median PFS of patients with only bone metastasis and visceral metastasis were similar (7.2 vs 6.4 months, P=0.96).
Conclusion: Everolimus plus exemestane is an effective and tolerable treatment choice in the later-lines in the treatment of HR-positive HER2-negative MBC.
Keywords
Kaynakça
- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
- 2. Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005. PMID: 29132568; PMCID: PMC5715810.
- 3. Perou CM, Sorlie T, Eisen MB,van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
- 4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. doi: 10.1073/pnas.191367098. PMID: 11553815; PMCID: PMC58566.
- 5. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009;20:628–35.
- 6. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol. 2008;39:506–13.
- 7. Desmedt C, Sotiriou C, Piccart-Gebhart MJ. Development and validation of gene expression profile signatures in early-stage breast cancer. Cancer Invest. 2009;27:1–10.
- 8. Iwamoto T, Pusztai L. Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med. 2010;2:81.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Onkoloji ve Karsinogenez
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
1 Haziran 2020
Gönderilme Tarihi
30 Mayıs 2020
Kabul Tarihi
16 Haziran 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 4 Sayı: 6
APA
Yıldız, F., & Öksüzoğlu, B. (2020). Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Surgery and Medicine, 4(6), 443-446. https://doi.org/10.28982/josam.745731
AMA
1.Yıldız F, Öksüzoğlu B. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. J Surg Med. 2020;4(6):443-446. doi:10.28982/josam.745731
Chicago
Yıldız, Fatih, ve Berna Öksüzoğlu. 2020. “Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer”. Journal of Surgery and Medicine 4 (6): 443-46. https://doi.org/10.28982/josam.745731.
EndNote
Yıldız F, Öksüzoğlu B (01 Haziran 2020) Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Surgery and Medicine 4 6 443–446.
IEEE
[1]F. Yıldız ve B. Öksüzoğlu, “Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer”, J Surg Med, c. 4, sy 6, ss. 443–446, Haz. 2020, doi: 10.28982/josam.745731.
ISNAD
Yıldız, Fatih - Öksüzoğlu, Berna. “Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer”. Journal of Surgery and Medicine 4/6 (01 Haziran 2020): 443-446. https://doi.org/10.28982/josam.745731.
JAMA
1.Yıldız F, Öksüzoğlu B. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. J Surg Med. 2020;4:443–446.
MLA
Yıldız, Fatih, ve Berna Öksüzoğlu. “Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer”. Journal of Surgery and Medicine, c. 4, sy 6, Haziran 2020, ss. 443-6, doi:10.28982/josam.745731.
Vancouver
1.Fatih Yıldız, Berna Öksüzoğlu. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. J Surg Med. 01 Haziran 2020;4(6):443-6. doi:10.28982/josam.745731